Published online Jul 27, 2025. doi: 10.4254/wjh.v17.i7.106253
Revised: March 26, 2025
Accepted: June 24, 2025
Published online: July 27, 2025
Processing time: 155 Days and 12.5 Hours
Hepatic manifestations in chronic lymphocytic leukemia (CLL) are common: Elevation of liver enzymes frequently occurs, and differential diagnosis is often challenging. Liver infiltration by leukemic cells, primary and secondary hepatic malignancies, drug-induced hepatotoxicity, immunological disorders, and infections have been reported. Nevertheless, syncytial giant cell hepatitis (GCH) as a manifestation of autoimmune hepatitis in patients with CLL is an extremely rare condition, currently reported only in anecdotal cases.
Here, we report the case of a 62-year-old Caucasian woman affected by CLL, who developed GCH with peculiar histopathological features. The patient was evaluated for abnormal liver test results. Liver histology revealed significant inflammatory lymphomononuclear infiltrates with a plasma cell component, widespread syncytial changes in the hepatocytes with gigantocellular features, hepatocyte rosettes, and the typical feature of emperipolesis, consistent with a diagnosis of GCH. The patient was treated with corticosteroids and mycophenolate mofetil, resulting in a complete biochemical response.
Early histological diagnosis of GCH is crucial in patients with CLL, with mycophenolate mofetil representing a promising treatment option.
Core Tip: The association between chronic lymphocytic leukemia (CLL) and syncytial giant cell hepatitis (GCH) is rare, with only a few cases reported in the literature. For this reason, early diagnosis is essential to prevent liver fibrosis and distinguish GCH from other causes of liver disorders. Active immunosuppressive therapy may be beneficial for patients with GCH, with mycophenolate mofetil emerging as a promising therapeutic option. Several studies have suggested a modified expression of toll-like receptors (TLRs) in CLL, potentially contributing to autoimmune complications. Further studies are needed to evaluate the role of TLR4 in autoimmune hepatitis development in patients with CLL.